Drug Interactions and Precautions with Clonidine, Strattera, and Dextromethorphan

Introduction to Combination Therapy

The American Academy of Child and Adolescent Psychiatry recommends cautious use of dextromethorphan with other serotonergic drugs, including SNRIs like atomoxetine, due to the risk of serotonin syndrome 1

Obtain baseline cardiovascular assessment before initiating the combination of clonidine and Strattera, including detailed personal and family cardiac history, baseline heart rate and blood pressure, and consider ECG if any cardiac risk factors exist 2, 3
Clonidine can cause bradycardia, hypotension, and AV conduction abnormalities, with documented cases of complete AV block when combined with other cardiac-active medications 2, 3
Exercise extreme caution in patients with AV conduction disease, as the combination significantly increases the risk of complete heart block 2

Start clonidine at the absolute minimum dose of 0.05 mg at bedtime, with slow titration not exceeding 0.3 mg/day 2, 3
When combining with atomoxetine, start atomoxetine at 40 mg daily and adjust only every 7-14 days, with maximum dosing of 1.4 mg/kg/day or 100 mg/day 2, 3

Baseline and periodic heart rate and blood pressure measurements are necessary, along with ECG monitoring if any cardiac risk factors are present 2, 3
Patients with hepatic insufficiency require lower doses of atomoxetine and more frequent monitoring 2, 3
Be alert for rebound hypertension if clonidine is abruptly discontinued 3

Dextromethorphan is a serotonergic medication that can trigger serotonin syndrome when combined with other serotonergic drugs, including SNRIs like atomoxetine 1
Serotonin syndrome symptoms can arise within 24 to 48 hours after combining medications and are characterized by mental status changes, neuromuscular hyperactivity, and autonomic hyperactivity 1
Advanced symptoms include fever, seizures, arrhythmias, and unconsciousness, which can lead to fatalities 1

When combining two or more non-MAOI serotonergic drugs, start the second drug at a low dose, increase slowly, and monitor for symptoms, especially in the first 24 to 48 hours after dosage changes 1
The combination dextromethorphan/quinidine should be used with caution due to limited efficacy in certain populations while potentially increasing the risk of falls and drug-drug interactions 4, 5

Co‑administration of dextromethorphan and losartan does not require dose adjustment or special monitoring because losartan is primarily metabolized by CYP2C9 and CYP3A4 (not CYP2D6) and there are no pharmacodynamic interactions between an angiotensin‑receptor blocker and a serotonergic cough suppressant. 6

Clinical data indicate that dextromethorphan provides limited benefit for cough suppression across most respiratory conditions. 6
In patients with acute cough due to the common cold, over‑the‑counter combination cold medications—including dextromethorphan—are not recommended until randomized controlled trials demonstrate clear efficacy. 6

If fluoxetine must be continued, the lowest effective dose of dextromethorphan (≤ 15 mg) should be used, with close monitoring for serotonin‑syndrome symptoms during the first 24–48 hours after initiation or any dose change. 6